Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1648 1653 1671 1672
This examiner grants 47% of resolved cases
Samadhan Jaising Jadhao is an examiner in Tech Center 1600 and Art Unit 1648. He has 64 resolved cases. His allowance rate is 46.9 percent, meaning fewer than half of his cases result in a patent grant. This 46.9 percent rate suggests a rigorous examination style where applicants must provide strong technical evidence to overcome rejections and secure their intellectual property rights.
The interview lift is 46.2 percent. This 46.2 percent lift is substantial, indicating that an interview can significantly increase the chances of an allowance. Given the 46.9 percent baseline, an interview is a highly recommended tactic for practitioners, as direct communication with the examiner appears to be a critical factor in reaching a favorable outcome in this docket.
The median days to allowance is 1334. This 1334 day period represents the typical time to grant for successful applications. Applicants should plan for a 1334 day pendency when navigating prosecution with this examiner, which reflects the time required to reach a final resolution in these 64 resolved cases.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 17769940 | METHODS FOR ULTRASENSITIVE DETECTION OF PROTEIN AND CELLULAR BIOMARKERS | Final Rejection | GEORGIA TECH RESEARCH CORPORATION |
| 18270131 | CROSS-NEUTRALIZING SARS-COV2 ANTIBODIES | Non-Final OA | California Institute of Technology |
| 18273466 | T CELL-DIRECTED ANTI-CANCER VACCINES AGAINST COMMENSAL VIRUSES FOR TREATING MUCOSAL CARCINOMAS | Non-Final OA | The General Hospital Corporation |
| 17612426 | DOSAGE REGIMENS FOR VACCINES | Final Rejection | Gilead Sciences, Inc. |
| 18040920 | Devices and Methods for Detection of Viruses from Exhaled Breath | Final Rejection | Northeastern University |
| 18461955 | MODIFIED POLYNUCLEOTIDES ENCODING THE SARS-COV-2 SPIKE PROTEIN FOR SAFER DESIGNS OF CORONAVIRUS VACCINES | Non-Final OA | University of Pittsburgh - Of the Commonwealth System of Higher Education |
| 18557787 | ENGINEERED INFLUENZA VIRUSES EXPRESSING SARS-COV-2 ANTIGENS, VACCINES AND METHODS OF MAKING AND USING THE SAME | Non-Final OA | Duke University |
| 18041025 | CORONAVIRUS POINT-OF-CARE AGGLUTINATION ASSAY | Final Rejection | Veravas, Inc. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy